ModifiedCentenePolicy CP.MP.248

Facility-based Sleep Studies for Obstructive Sleep Apnea

Defines medical necessity criteria for facility-based full-night and split-night PSG and facility-based CPAP/BiPAP titration for suspected obstructive sleep apnea in non-Medicare Centene-affiliated health plans for adults (≥18 years).

Policy Summary

PayerCentene

PolicyFacility-based Sleep Studies for Obstructive Sleep Apnea

Policy CodePolicy CP.MP.248

Change TypeCriteria revisions and operational clarifications (material)

Effective Date

Next Review Date

Key ActionDocument suspected OSA and reasons HSAT is not appropriate, and include prior HSAT or APAP/autotitration results when applicable.

SourceLink

POLICY UPDATE CHANGES

Expanded scope to explicitly include split-night studies and facility-based titration.

Added criteria allowing facility testing for mission-critical workers and members with BMI ≥50 kg/m2.

Clarified requirements around prior HSAT and APAP/autotitration failure as indications for facility-based titration.

Specified removal of left ventricular EF criterion in favor of NYHA heart failure classification.

Changed I.B.3 into two indications in I.B.3 and 4 for clarity.

Updated wording in Criteria I.B.8.a.v. and added addition of disorders that interfere with HSAT.

Removed 'moderate to-to-high-risk' verbiage in Criteria I.B.8.b. and updated outline of this criteria.

Removed Epworth Sleepiness Scale criteria from I.B.8.b.i.

Added Criteria I.B.8.b.ii.c) which states, 'Diagnosis of hypertension.'

Minor rewording in Criteria II. with no impact to criteria.

3Main policy sections

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Medical Necessity Criteria for Facility-Based PSG and Titration

Initial Therapy

Covered when ALL of the following are met

ref

title

ref_extra

title_extra

b0_0

Repeat Therapy

Covered when ALL of the following are met

Repeat PSG criteria

The requested study and any previous studies amount to two or fewer per rolling year<= 2 studies per rolling year
Section II.B
Indications for repeat testing
- Oral appliance has been adjusted for fit and requires assessment of efficacy
  II.C.1
- A change of device is needed due to intolerance of current device
  II.C.2
- Assessment of whether PAP treatment settings need to be changed, including continued symptoms despite adherent use (at least 4 hours/night for 70% of nights over a 30-day period)>=4 hours/night for 70% of nights over 30 days

ref

title

ref_extra

title_extra

b0_1

ref_extra2

Titration

Covered when ONE of the following is met

Titration criteria: A) Meets criteria in section I for facility-based sleep study and has not attempted a home-based study for titration of APAP; OR B) Diagnosed with OSA during HSAT and there is evidence or documentation of failure of an APAP trial including downloaded compliance data

Section III.A and III.B

Not Supported/Informational

Actigraphy stance: Insufficient evidence to support use of actigraphy testing alone for diagnosis of obstructive sleep apnea

Actigraphy (CPT 95803) alone is not supported

Revisions to coverage criteria

Policy criteria were revised; specific covered indications and clarifications were updated as described below.

edits_summary: I.B.3 was split into two indications (now I.B.3 and I.B.4); wording updated in I.B.8.a.v. and disorders that interfere with HSAT were added as indications for facility PSG; removal of 'moderate-to-high-risk' verbiage from I.B.8.b and removal of Epworth Sleepiness Scale criteria from I.B.8.b.i; added I.B.8.b.ii.c) 'Diagnosis of hypertension.'; minor rewording in Criteria II with no impact to criteria.

See approval date 10/24 and revision summary

The policy states that actigraphy (CPT 95803) alone is not supported

The document notes that prior language was revised in the most recent update; the excerpted portion does not present explicit exclusions resulting from those edits. The summary of changes describes splitting an indication into two, wording updates and additions (including disorders that interfere with HSAT), and removal of some prior language such as Epworth Sleepiness Scale criteria, but the full text of any removed exclusions is not included here.

Home sleep apnea testing (HSAT) measures fewer physiologic variables than facility-based polysomnography and can miss events, particularly in patients with atypical or non-respiratory sleep disorders or significant cardiorespiratory comorbidity. For such patients the policy indicates that HSAT alone is insufficient and facility-based polysomnography is indicated per the listed medical necessity criteria.

The policy provides medical necessity guidance for facility-based polysomnography and titration; however, this excerpt does not list specific standalone 'not medically necessary' determinations beyond the documented statements that actigraphy alone is unsupported and that HSAT may be inadequate for certain patients. Providers should follow the policy criteria and applicable plan administrative rules when seeking coverage determinations.

CPT Codes, Limits, and Age Thresholds

Covered CPT CodesCPTCovered

95807	Sleep study, simultaneous recording of ventilation, respiratory effort, ECG or heart rate, and oxygen saturation, attended by a technologist.
95808	Polysomnography; any age, sleep staging with 1-3 additional parameters of sleep, attended by a technologist.
95810	Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, attended by a technologist.
95811	Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bilevel ventilation, attended by a technologist.

Not Covered CPT CodesCPTNot Covered

95803

Actigraphy testing, recording, analysis, interpretation, and report (minimum of 72 hours to 14 consecutive days of recording)

Maximum facility-based studies per rolling year

Maximum facility-based studies per rolling yearTwo or less per rolling year (requested study plus any prior studies must total ≤2 per rolling year).

ApplicabilityApplies to repeat facility-based PSG or split-night studies after an initial study for members/enrollees ≥18 years.

Related criteriaAll initial-section I.B criteria must be met in addition to the rolling-year limit for repeat testing to be covered.

Age threshold

Age thresholdMembers/enrollees must be ≥ 18 years of age for coverage of initial, repeat, and titration facility-based PSG as specified in this policy.

Scope

Prior Authorization, Documentation, and Operational Guidance

Prior Authorization
Prior Authorization Required
Prior authorization: Requests for facility-based initial, repeat, and titration polysomnography (PSG) or split-night studies require prior authorization and must demonstrate medical necessity per the policy criteria. Providers should follow applicable Health Plan-level administrative policies and procedures when submitting authorization requests.
Prior authorization required for facility-based initial, repeat, and titration PSG/split-night studies
Adhere to Health Plan administrative rules and coverage documents when seeking authorization

Documentation Required
Required Clinical Documentation
Documentation: Providers must document suspected obstructive sleep apnea (OSA) and why home sleep apnea testing (HSAT) is not appropriate, choosing from the policy's enumerated reasons (e.g., HSAT unavailable; patient unable to operate HSAT equipment; prior HSAT negative or inadequate; chronic opioid use; low pretest probability with clinical concern; mission-critical occupation; BMI ≥50 kg/m2; significant cardiopulmonary comorbidities such as NYHA class III–IV heart failure). For repeat studies, document prior study dates and indications, and ensure the requested study and any previous studies total two or fewer per rolling year when applicable. For titration studies, document prior HSAT diagnosis of OSA and evidence of APAP trial failure when applicable (e.g., downloaded compliance or efficacy data).

Clinical Background on Obstructive Sleep Apnea and Testing Modalities

Obstructive sleep apnea (OSA) is characterized by partial or complete upper airway collapse during sleep that produces recurrent apneas and hypopneas, leading to daytime sleepiness and increased cardiopulmonary risk. Polysomnography (PSG) is the gold-standard, comprehensive, facility-based overnight study that records sleep stages, respiratory flow and effort, pulse oximetry and other physiologic parameters to establish a diagnosis and guide PAP titration. Home sleep apnea testing (HSAT) is an alternative for selected adults with a high pretest probability of moderate-to-severe uncomplicated OSA but measures fewer physiologic variables and may under-detect events or miss non-respiratory sleep disorders or important comorbidities; therefore facility-based PSG is preferred when those conditions are present.

Key Definitions Used in This Policy

Polysomnography (PSG)

DefinitionComprehensive, facility-based overnight sleep study monitoring sleep stages, respiratory flow and effort, pulse oximetry, ECG/heart rate, ventilation, and other physiologic parameters; used for diagnosis of sleep disorders and PAP titration.

FormatsPerformed as a full-night study or split-night study; split-night may include diagnostic recording followed by onsite PAP titration the same night.

Clinical useGold standard diagnostic test for OSA and indicated when HSAT is inappropriate or additional physiologic monitoring is required (e.g., suspected non-respiratory sleep disorders, significant cardiopulmonary disease).

Home Sleep Apnea Testing (HSAT)

DefinitionPortable testing performed at home using type 3 or type 4 devices that measure fewer physiologic variables than facility PSG; may include nasal pressure, respiratory effort, and oximetry depending on device type.

Policy Summary

PayerCentene

PolicyFacility-based Sleep Studies for Obstructive Sleep Apnea

Policy CodePolicy CP.MP.248

Change TypeCriteria revisions and operational clarifications (material)

Effective Date

Next Review Date

Key ActionDocument suspected OSA and reasons HSAT is not appropriate, and include prior HSAT or APAP/autotitration results when applicable.

SourceLink

On This Page

Prior Authorization
Titration Studies After HSAT/APAP
Titration following HSAT/APAP trial: Facility-based CPAP/BiPAP titration is medically necessary when the member meets facility-based PSG criteria and has not attempted a home-based APAP titration, or when OSA was diagnosed by HSAT and there is documentation of APAP trial failure. Failure documentation may include downloaded compliance data, persistence of symptoms despite adherent APAP use, or inadequate autotitration results.
Titration medically necessary if no attempted home APAP titration and facility criteria are met
Titration medically necessary when HSAT diagnosed OSA and APAP trial failed with documented evidence (e.g., device downloads, inadequate autotitration)

Denial Risk
Documentation, Applicability, and Denial Risk
Applicability and coverage limits: The clinical policy is a guide to medical necessity and does not guarantee payment. Coverage decisions are subject to the Health Plan's terms, conditions, exclusions, and applicable state or federal requirements. Requests that do not meet the policy's medical necessity criteria (including required trial requirements or documentation) are at risk for denial. Providers should consult member-specific coverage documents and Health Plan administrative policies for benefit applicability.
This policy guides medical necessity determinations but is not a contract or payment guarantee
Coverage is subject to member-specific benefit documents, state/federal law, and Health Plan administrative policies
Incomplete documentation or failure to meet criteria may result in claim denial

HSAT vs facility-based PSG

When HSAT is preferredHSAT may be appropriate for adults with high pretest probability of moderate-to-severe uncomplicated OSA and no significant comorbidities or suspected non-respiratory sleep disorders.

When facility-based PSG is preferredFacility PSG is preferred when HSAT is unavailable, the patient cannot operate/tolerate HSAT, prior HSAT was negative or inadequate, there is chronic opioid use, low pretest probability of OSA, mission-critical employment, BMI ≥50 kg/m2, significant pulmonary disease, need for PAP titration, or suspected non-respiratory sleep disorders or significant cardiorespiratory disease.

Diagnostic trade-offsHSAT measures fewer physiologic variables and may miss mild disease or non-respiratory disorders; PSG provides comprehensive monitoring and is used for diagnosis and PAP titration when additional data are needed.